WA
BCAX

WPG Advisers’s Bicara Therapeutics BCAX Stock Holding History

WPG Advisers’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$891 Buy
30
+2
+7% +$45 ﹤0.01% 1353
2026
Q1 		$557 Buy
28
+2
+8% +$34 ﹤0.01% 1348
2025
Q4 		$438 Buy
+26
New +$444 ﹤0.01% 1397

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

WPG Advisers's BCAX Position: Q2 2026 in Review

WPG Advisers increased its Bicara Therapeutics (BCAX) stake by 7.1% in Q2 2026, buying an estimated $45 and bringing the position to 30 shares worth $891. The position accounts for ﹤0.01% of the portfolio, ranked #1353.

WPG Advisers first reported a position in BCAX in Q4 2025 and has held it in 3 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • WPG Advisers held 30 shares of Bicara Therapeutics worth $891 as of Q2 2026.
  • WPG Advisers bought 2 Bicara Therapeutics shares in Q2 2026, an estimated $45.
  • Bicara Therapeutics made up ﹤0.01% of WPG Advisers's portfolio in Q2 2026, its #1353 holding.
  • WPG Advisers first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.